{"id":47825,"date":"2022-03-17T09:35:16","date_gmt":"2022-03-16T22:35:16","guid":{"rendered":"https:\/\/hudson.org.au?post_type=hdsn_news_post&p=47825"},"modified":"2022-06-20T14:53:59","modified_gmt":"2022-06-20T04:53:59","slug":"targeting-viral-lung-infections-two-ways","status":"publish","type":"hdsn_news_post","link":"https:\/\/hudson.org.au\/news\/targeting-viral-lung-infections-two-ways\/","title":{"rendered":"Targeting viral lung infections two ways"},"content":{"rendered":"\n

A new anti-viral drug to target the cause of viral lung infections and the infection itself, could be a game-changer in treating severe influenza<\/a>.<\/p>\n\n\n\n

\"Associate
Associate Professor Michelle Tate<\/em><\/figcaption><\/figure><\/div>\n\n\n\n

There are currently few effective drugs available to treat severe viral lung infections, which can be fatal when our body\u2019s immune system overacts.<\/p>\n\n\n\n

Associate Professor Michelle Tate<\/a>, from Hudson Institute\u2019s Viral Immunity and Immunopathology<\/a> Research group, is working with Lateral Pharma Pty Ltd, developing drugs to treat severe lung infections including influenza and the common cold.<\/p>\n\n\n\n

\u201cNew drugs which dampen damaging inflammation and reduce the impact of respiratory viral infections are desperately needed,\u201d A\/Prof Tate said.<\/p>\n\n\n\n

Finding new influenza drugs <\/h2>\n\n\n\n

\u201cEach year in Australia on average there are around 3,500 deaths linked to flu and 18,000 hospitalisations,\u201d she said. \u201cWhen patients with severe flu are admitted to hospital there are no effective drugs available to reduce the response to the virus.\u201d<\/p>

Lateral Pharma CEO, David Kenley OAM said there is a clear need for new antiviral and anti-inflammatory drugs.<\/p>

\u201cThey are needed for the treatment of a number of significant conditions caused by viruses which are not at present adequately controlled, including upper and lower respiratory tract infections and influenza,\u201d he said.  \u201cThis need is particularly prevalent in the elderly, where death rates from viral attack are higher.\u201d<\/p><\/blockquote>\n\n\n\n

Viral infections replicate when the virus infects its host by attaching to the host cells. While current antiviral treatments target the virus itself, these drugs target the host cell, using naturally derived protective proteins to fight the virus and stop it replicating.  <\/p>\n\n\n\n

Anti-inflammatory and anti-viral efficacy<\/h2>\n\n\n\n

Already A\/Prof Tate and her team have shown that these drugs display both anti-inflammatory and anti-viral efficacy in preclinical models.<\/p>\n\n\n\n

To bring them to patients, the team is performing critical \u2018proof of concept\u2019 and mechanistic studies in influenza and respiratory syncytial virus models, with the view to developing new drugs. <\/p>\n\n\n\n

\u201cThese drugs have been shown to be safe in humans and our studies will facilitate the design of a clinical trial and translation into the clinic,\u201d A\/Prof Tate said.<\/p><\/blockquote>\n\n\n\n

\n \n
\n \n \n <\/div>\n
\n

Diseases we research<\/p>\n

\n Influenza | Learn more<\/span>\n \n <\/polygon>\n <\/svg>\n <\/p>\n <\/div>\n <\/a>\n <\/div>\n \n\n\n

Funders |<\/strong> Lateral Pharma Pty Ltd<\/a><\/p>\n\n\n\n

Contact us<\/strong><\/h3>\n\n\n\n

Hudson Institute communications
t:\u00a0<\/strong>+ 61 3 8572 2761
e:\u00a0<\/strong>communications@hudson.org.au<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

A new anti-viral drug to target the cause of viral lung infections and the infection itself could be a game-changer in treating severe influenza.…  Read more<\/a><\/p>\n","protected":false},"featured_media":47794,"menu_order":0,"template":"","issue":[],"tag":[135],"story-type":[86],"treatment-type":[],"class_list":["post-47825","hdsn_news_post","type-hdsn_news_post","status-publish","has-post-thumbnail","hentry","tag-business-development","story-type-industry"],"acf":[],"yoast_head":"\nTargeting viral lung infections two ways - Hudson Institute of Medical Research<\/title>\n<meta name=\"description\" content=\"New anti-viral drug targeting the cause of viral lung infections could be a game-changer for treating severe influenza.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hudson.org.au\/news\/targeting-viral-lung-infections-two-ways\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Targeting viral lung infections two ways\" \/>\n<meta property=\"og:description\" content=\"New anti-viral drug targeting the cause of viral lung infections could be a game-changer for treating severe influenza.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hudson.org.au\/news\/targeting-viral-lung-infections-two-ways\/\" \/>\n<meta property=\"og:site_name\" content=\"Hudson Institute of Medical Research\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-20T04:53:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hudson.org.au\/wp-content\/uploads\/2022\/03\/AProf-Michelle-Tate-News-story.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/targeting-viral-lung-infections-two-ways\\\/\",\"url\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/targeting-viral-lung-infections-two-ways\\\/\",\"name\":\"Targeting viral lung infections two ways - Hudson Institute of Medical Research\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/hudson.org.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/targeting-viral-lung-infections-two-ways\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/targeting-viral-lung-infections-two-ways\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/hudson.org.au\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/AProf-Michelle-Tate-News-story.jpg\",\"datePublished\":\"2022-03-16T22:35:16+00:00\",\"dateModified\":\"2022-06-20T04:53:59+00:00\",\"description\":\"New anti-viral drug targeting the cause of viral lung infections could be a game-changer for treating severe influenza.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/targeting-viral-lung-infections-two-ways\\\/#breadcrumb\"},\"inLanguage\":\"en-AU\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/hudson.org.au\\\/news\\\/targeting-viral-lung-infections-two-ways\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-AU\",\"@id\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/targeting-viral-lung-infections-two-ways\\\/#primaryimage\",\"url\":\"https:\\\/\\\/hudson.org.au\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/AProf-Michelle-Tate-News-story.jpg\",\"contentUrl\":\"https:\\\/\\\/hudson.org.au\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/AProf-Michelle-Tate-News-story.jpg\",\"width\":600,\"height\":600,\"caption\":\"Associate Professor Michelle Tate from the Viral Immunity and Immunopathology Research Group at Hudson Institute of Medical Research\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/targeting-viral-lung-infections-two-ways\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/hudson.org.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/hudson.org.au\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Targeting viral lung infections two ways\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/hudson.org.au\\\/#website\",\"url\":\"https:\\\/\\\/hudson.org.au\\\/\",\"name\":\"Hudson Institute of Medical Research\",\"description\":\"Transforming lives through scientific discovery.\",\"publisher\":{\"@id\":\"https:\\\/\\\/hudson.org.au\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/hudson.org.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-AU\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/hudson.org.au\\\/#organization\",\"name\":\"Hudson Institute of Medical Research\",\"url\":\"https:\\\/\\\/hudson.org.au\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-AU\",\"@id\":\"https:\\\/\\\/hudson.org.au\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/hudson.org.au\\\/wp-content\\\/uploads\\\/2017\\\/05\\\/hudson-logo-1.jpg\",\"contentUrl\":\"https:\\\/\\\/hudson.org.au\\\/wp-content\\\/uploads\\\/2017\\\/05\\\/hudson-logo-1.jpg\",\"width\":1200,\"height\":316,\"caption\":\"Hudson Institute of Medical Research\"},\"image\":{\"@id\":\"https:\\\/\\\/hudson.org.au\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Targeting viral lung infections two ways - Hudson Institute of Medical Research","description":"New anti-viral drug targeting the cause of viral lung infections could be a game-changer for treating severe influenza.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hudson.org.au\/news\/targeting-viral-lung-infections-two-ways\/","og_locale":"en_US","og_type":"article","og_title":"Targeting viral lung infections two ways","og_description":"New anti-viral drug targeting the cause of viral lung infections could be a game-changer for treating severe influenza.","og_url":"https:\/\/hudson.org.au\/news\/targeting-viral-lung-infections-two-ways\/","og_site_name":"Hudson Institute of Medical Research","article_modified_time":"2022-06-20T04:53:59+00:00","og_image":[{"width":600,"height":600,"url":"https:\/\/hudson.org.au\/wp-content\/uploads\/2022\/03\/AProf-Michelle-Tate-News-story.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/hudson.org.au\/news\/targeting-viral-lung-infections-two-ways\/","url":"https:\/\/hudson.org.au\/news\/targeting-viral-lung-infections-two-ways\/","name":"Targeting viral lung infections two ways - Hudson Institute of Medical Research","isPartOf":{"@id":"https:\/\/hudson.org.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/hudson.org.au\/news\/targeting-viral-lung-infections-two-ways\/#primaryimage"},"image":{"@id":"https:\/\/hudson.org.au\/news\/targeting-viral-lung-infections-two-ways\/#primaryimage"},"thumbnailUrl":"https:\/\/hudson.org.au\/wp-content\/uploads\/2022\/03\/AProf-Michelle-Tate-News-story.jpg","datePublished":"2022-03-16T22:35:16+00:00","dateModified":"2022-06-20T04:53:59+00:00","description":"New anti-viral drug targeting the cause of viral lung infections could be a game-changer for treating severe influenza.","breadcrumb":{"@id":"https:\/\/hudson.org.au\/news\/targeting-viral-lung-infections-two-ways\/#breadcrumb"},"inLanguage":"en-AU","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hudson.org.au\/news\/targeting-viral-lung-infections-two-ways\/"]}]},{"@type":"ImageObject","inLanguage":"en-AU","@id":"https:\/\/hudson.org.au\/news\/targeting-viral-lung-infections-two-ways\/#primaryimage","url":"https:\/\/hudson.org.au\/wp-content\/uploads\/2022\/03\/AProf-Michelle-Tate-News-story.jpg","contentUrl":"https:\/\/hudson.org.au\/wp-content\/uploads\/2022\/03\/AProf-Michelle-Tate-News-story.jpg","width":600,"height":600,"caption":"Associate Professor Michelle Tate from the Viral Immunity and Immunopathology Research Group at Hudson Institute of Medical Research"},{"@type":"BreadcrumbList","@id":"https:\/\/hudson.org.au\/news\/targeting-viral-lung-infections-two-ways\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hudson.org.au\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/hudson.org.au\/news\/"},{"@type":"ListItem","position":3,"name":"Targeting viral lung infections two ways"}]},{"@type":"WebSite","@id":"https:\/\/hudson.org.au\/#website","url":"https:\/\/hudson.org.au\/","name":"Hudson Institute of Medical Research","description":"Transforming lives through scientific discovery.","publisher":{"@id":"https:\/\/hudson.org.au\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hudson.org.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-AU"},{"@type":"Organization","@id":"https:\/\/hudson.org.au\/#organization","name":"Hudson Institute of Medical Research","url":"https:\/\/hudson.org.au\/","logo":{"@type":"ImageObject","inLanguage":"en-AU","@id":"https:\/\/hudson.org.au\/#\/schema\/logo\/image\/","url":"https:\/\/hudson.org.au\/wp-content\/uploads\/2017\/05\/hudson-logo-1.jpg","contentUrl":"https:\/\/hudson.org.au\/wp-content\/uploads\/2017\/05\/hudson-logo-1.jpg","width":1200,"height":316,"caption":"Hudson Institute of Medical Research"},"image":{"@id":"https:\/\/hudson.org.au\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/hdsn_news_post\/47825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/hdsn_news_post"}],"about":[{"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/types\/hdsn_news_post"}],"version-history":[{"count":0,"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/hdsn_news_post\/47825\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/media\/47794"}],"wp:attachment":[{"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/media?parent=47825"}],"wp:term":[{"taxonomy":"issue","embeddable":true,"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/issue?post=47825"},{"taxonomy":"tag","embeddable":true,"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/tag?post=47825"},{"taxonomy":"story-type","embeddable":true,"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/story-type?post=47825"},{"taxonomy":"treatment-type","embeddable":true,"href":"https:\/\/hudson.org.au\/wp-json\/wp\/v2\/treatment-type?post=47825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}